Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. Dezember 2020 17:09 ET | Quelle: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement Copenhagen, Denmark; December 15, 2020 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses...
15. Dezember 2020 17:01 ET | Quelle: Genmab A/S

Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Company Announcement Copenhagen, Denmark; December 15, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 9,663 restricted stock units to members of...
03. Dezember 2020 11:41 ET | Quelle: Genmab A/S

Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer

Media Release Copenhagen, Denmark, December 3, 2020 Janssen submitted a BLA to U.S. FDA for amivantamab for patients with non-small cell lung cancer with epidermal growth factor receptor Exon 20...
24. November 2020 10:40 ET | Quelle: Genmab A/S

Genmab Announces Enapotamab Vedotin Update

Company Announcement Genmab will not advance the development of enapotamab vedotinData from expansion cohorts did not meet stringent criteria for proof-of-conceptGenmab to prioritize development of...
10. November 2020 14:57 ET | Quelle: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement Copenhagen, Denmark; November 10, 2020 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,402 shares as a consequence of the exercise of employee warrants. The...
10. November 2020 07:59 ET | Quelle: Genmab A/S

Genmab to Present at Jefferies Virtual London Healthcare Conference

Media Release Copenhagen, Denmark, November 10, 2020 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D. and CFO Anthony Pagano, will present an update at the Jefferies...
05. November 2020 08:39 ET | Quelle: Genmab A/S

Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Company Announcement First Phase 3 study of epcoritamab as part of broad clinical development plan with AbbVieDiffuse Large B-cell Lymphoma is the most common form of non-Hodgkin’s lymphoma worldwide...
05. November 2020 06:26 ET | Quelle: Genmab A/S

Genmab Announces that Janssen has Submitted a Type II Variation Application to the European Medicines Agency for use of Subcutaneous DARZALEX® (daratumumab) in Patients with Light-chain (AL) amyloidosis

Media Release Copenhagen, Denmark, November 5, 2020 Janssen submitted a Type II variation application to the European Medicines Agency for subcutaneous formulation of daratumumab in combination...
04. November 2020 11:04 ET | Quelle: Genmab A/S

Genmab Announces Financial Results for the First Nine Months of 2020

November 4, 2020; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2020HighlightsNovartis granted U.S. FDA approval for Kesimpta® (ofatumumab) in relapsing multiple...
04. November 2020 10:13 ET | Quelle: Genmab A/S

Genmab Announces Data to be Presented at 2020 ASH Annual Meeting

Media Release Copenhagen, Denmark, November 4, 2020 More than 40 abstracts on Genmab owned and partnered programs scheduled for presentation at ASHData from ongoing Phase I/II epcoritamab trial...

Vorherige Seite

Nächste Seite